Penn ophthalmologists are making headlines with cutting-edge research and specialized patient care.
Recent news through 2025
- June 6, 2024: Lama Al-Aswad, MD, MPH. Penn Engineering Today: Six Interdisciplinary Projects Receive Support from ASSET Center Seed Grants in Trustworthy AI Research for Medicine.
- October 4, 2024: Lama Al-Aswad, MD, MPH. Penn Engineering Today: Revolutionizing Cardiovascular Risk Assessment with AI.
- October 21, 2024: Bennie Jeng, MD, MS. Penn Medicine: Long Term Antiviral Use is Key to Ocular Shingles Treatment.
- August 4, 2025: William A. Beltran, DVM, PhD, DECVO. Penn Vet News: Penn Vet Researchers Evaluate a New Device That Could Streamline Vision-Saving Therapies.
- August 26, 2025: Vatinee Bunya, MD. The Rheumatologist: Sjögren’s Dry Eye Requires Collaboration Among Eye Doctors, Rheumatologists.
- August 28, 2025: Mina Massaro-Giordano, MD. NYU Langone News: Renowned Specialist to Lead New Dry Eye Service at NYU Langone Eye Center.
- August 28, 2025: Rithu Ramchandran, MD, MSc. Healio: AI Shows Promise in Glaucoma Care.
- Various: Artur Cideciyan, PhD, and Tomas Aleman, MD. Penn CHRD (Including):
- October 2025 (re CEP290 trial)
- Sepul Bio: Sepul Bio, an innovative business unit of Théa, doses first participant in Phase 3 HYPERION clinical trial of sepofarsen for CEP290-associated Leber congenital amaurosis type 10
- September 2025 (re LCA5 gene therapy)
- Ophthalmology Times: Positive pediatric data emerge from the OPGx-LCA5 phase 1/2 trial of Leber congenital amaurosis type 5
- Fierce Biotech: Opus sets sights on FDA talks after posting pediatric gene therapy data
- Stock Titan: Opus Genetics' LCA5 gene therapy shows 70% vision gain in teens
- Inside Precision Medicine: Braille to sight: Opus genetics’ gene therapy treats rare childhood blindness
- Opus Genetics: Opus Genetics reports positive pediatric data from OPGx-LCA5 phase 1/2 trial in Leber congenital amaurosis type 5 (LCA5)
- September 2024 (re GUCY2D-LCA1 gene therapy, * original reporting)
- MedicalNewsToday (*): Gene therapy for vision loss: Ongoing challenges
- WHYY (*): Penn researchers develop new gene therapy for previously untreatable eye disorder
- SciTechDaily: Seeing Is believing: The gene therapy breakthrough that’s giving sight to the blind
- MedPage Today (*): Gene therapy shows promise in rare eye disease that causes early blindness
- Medscape Medical News (*): Gene therapy shown to improve vision in congenital blindness
- STAT News (*): Q&A: Atsena Therapeutics’ gene therapy for inherited blindness shows promise
- European Pharmaceutical Review: Gene therapy trial facilitates major vision improvement
- Precision Medicine Online: Promising 12-month data on Atsena's LCA1 gene therapy bolsters case of pivotal trial
- Insight News: Gene therapy trial brings dramatic improvement in eyesight for patients
- HealthDay: Gene therapy reverses a rare cause of vision loss
- Correio Braziliense (*): Terapia genética melhora 10 mil vezes a visão de pacientes de doença rara [Gene therapy improves vision of rare disease patients 10,000 times ]
- US News & World Report: Gene Therapy Reverses a Rare Cause of Vision Loss
- UF News: Gene therapy restores vision in first-ever trial for rare, inherited blindness
- Atsena: Atsena therapeutics announces 12-month safety and efficacy data from phase I/II clinical trial of ATSN-101 in LCA1 published in The Lancet
- Penn Today: Gene therapy trial sees massive improvement in vision
- Penn Medicine News: 100x improvement in sight seen after gene therapy trial
- August 2024 (re LCA5 gene therapy)
- Opus Genetics: Opus genetics receives rare pediatric disease designation from the U.S. FDA for ocular gene therapy OPGx-LCA5 to treat rare inherited retinal disease LCA5
2022 news
- April 26, 2022: Brian VanderBeek. More Evidence That Fenofibrate Slows Diabetic Eye Disease. MedPage Today: A study led by Dr. VanderBeek found that the use of the drug fenofibrate is associated with a reduced risk of vision-threatening diabetic retinopathy.
- April 13, 2022: Eydie Miller-Ellis. 6 Steps to Help You Protect Your Vision. Times of Oman: Dr. Miller discusses the risk factors of glaucoma and preventative measures you can take to protect your vision.
- April 11, 2022: Brian VanderBeek. Fenofibrate Use May Reduce Progression to Vision-Threatening Diabetic Retinopathy. HCP Live: A study led by Dr. VanderBeek shows that the use of fenofibrate was associated with a decreased risk of the progression of vision-threatening diabetic retinopathy. The results were published in JAMA Ophthalmology.
- March 18, 2022: Joshua Dunaief. Judi Dench Health: 'I Can't do a Crossword' – Star on her Progressive Disease. Express: Dr. Dunaief shares advice to individuals with age-related macular degeneration about leading a healthy lifestyle.
- March 14, 2022: Gui-shuang Ying. Could Depression Make Dry Eye Worse? Health Day: A new study from Penn researchers, including Dr. Ying, shows a correlation between depression and severe dry eye symptoms.
- March 4, 2022: Joan O'Brien. Dr. Joan O'Brien Celebrated for Dedication to the Field of Ophthalmology. 24-7 Press Release: Dr. O'Brien has been included in Marquis Who's Who, which provides biographies of individuals with noteworthy accomplishments and prominence in their field.
- March 3, 2022: Eydie Miller-Ellis. Stated Meeting of Philadelphia City Council. Philadelphia City Council: Councilman Curtis Jones, Jr. introduces a Resolution honoring Dr. Miller's work in the community and beyond.
- March 2, 2022: Bennie H. Jeng, MD, Named Chair of Ophthalmology at Penn Medicine. Penn Medicine News: Bennie H. Cheng, MD has been named the Chair of the Department of Ophthalmology. Dr. Cheng will assume this role on July 1, 2022, succeeding Joan M. O'Brien, MD, who has served as chair for 12 years.
- January 20, 2022: Vatinee Bunya. Can Omicron Cause Itchy Eyes? Experts Explain. Prevention: Dr. Bunya discusses ways to treat itchy and irritated eyes due to Omicron.
Community outreach
The Scheie Eye Institute is committed to making an impact through various service initiatives in the community. Our faculty and trainees travel throughout Philadelphia and across the globe to care for all populations, providing free eye care and health screenings.
Penn sight savers
Penn Sight Savers is a student-run program that educates the community on the importance of regular eye exams, and offers free glaucoma screenings to patients across Philadelphia. Medical students collaborate with Scheie glaucoma specialists to host screening stations at local health fairs and community events. During these events, students and physicians assess the patient's vision, specifically screening for glaucoma. These assessments inform patients when they should seek more advanced screenings and/or treatment.
Puentes de Salud
Puentes de Salud, a healthcare clinic that treats the Latino population of Philadelphia, accommodates 10,000 visits each year. This center includes an eye clinic, where Scheie physicians and medical students frequently volunteer their time. In the clinic, our physicians and students provide comprehensive ophthalmic care to patients.
For questions or for more information on Puentes de Salud, please contact info@puentesdesalud.org.
Community screening events
Several times a year, Scheie faculty and staff organize various screening events across Philadelphia. These events provide free health and eye screenings, typically for glaucoma or low vision, and offer visual device giveaways, educational materials, and other health and wellness related resources to members of the community.
To learn about partnership opportunities or for more information about Scheie's screening events, please contact Marquis Vaughn at 215-662-8023.
Vision loss support group
The Penn Center for Low Vision Rehabilitation's Vision Loss Support Group provides support to patients with no remaining surgical or medical options to improve their declining vision. Meetings consist of individuals with a range of visual abilities, all of whom share a desire for emotional support and encouragement.
The group hosts occasional guest speakers who share knowledge on various topics, including the assistive devices and technologies available for patients with vision loss. In addition to guest speakers, participants hold valuable open discussion during meetings.
International travel
Faculty have traveled to 30+ countries in the past five years to treat many different populations.